硕世生物
(688399)
| 流通市值：36.08亿 | | | 总市值：36.08亿 |
| 流通股本：5667.01万 | | | 总股本：5667.01万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 268,088,026.64 | 177,448,258.24 | 91,119,399.55 | 403,179,297.92 |
| 营业收入 | 268,088,026.64 | 177,448,258.24 | 91,119,399.55 | 403,179,297.92 |
| 二、营业总成本 | 308,029,355.8 | 196,326,361.15 | 88,153,703.32 | 618,868,942.98 |
| 营业成本 | 92,059,556.32 | 56,552,762.69 | 26,490,695.75 | 145,498,166.18 |
| 税金及附加 | 5,089,106.44 | 3,411,911.82 | 1,772,505.8 | 8,052,251.81 |
| 销售费用 | 98,044,768.7 | 65,516,664.68 | 28,549,156.64 | 200,232,962.7 |
| 管理费用 | 57,461,952.57 | 40,110,150.14 | 16,203,846.73 | 177,249,414.66 |
| 研发费用 | 72,683,955.39 | 46,770,081.96 | 19,762,499.26 | 135,532,978.11 |
| 财务费用 | -17,309,983.62 | -16,035,210.14 | -4,625,000.86 | -47,696,830.48 |
| 其中:利息费用 | 6,058,463.83 | 3,904,453.59 | 1,834,800.55 | 6,938,959.58 |
| 其中:利息收入 | 25,012,189.09 | 20,007,329.37 | 6,418,418.02 | 55,970,553.82 |
| 加:公允价值变动收益 | -6,501,055.88 | -3,951,763.43 | 3,176,155.66 | 13,116,997.99 |
| 加:投资收益 | -828,605.01 | -2,073,654.58 | -846,408.12 | 1,584,859.96 |
| 资产处置收益 | 2,221,823.99 | 1,556,757.11 | 886,454.11 | 3,884,684.32 |
| 资产减值损失(新) | -2,226,271.05 | -2,166,632.46 | 236,443.26 | -187,445,504.38 |
| 信用减值损失(新) | 31,058,163.92 | 23,970,128.38 | 3,007,631.6 | -29,396,687.08 |
| 其他收益 | 49,265,618.56 | 34,393,911.48 | 30,716,671.24 | 48,888,260.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 33,048,345.37 | 32,850,643.59 | 40,142,643.98 | -365,057,033.55 |
| 加:营业外收入 | 128,835.49 | 128,835.35 | 23,187.82 | 1,205,396.97 |
| 减:营业外支出 | 939,725.57 | 563,392.37 | 2,228.02 | 11,818,539.92 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 32,237,455.29 | 32,416,086.57 | 40,163,603.78 | -375,670,176.5 |
| 减:所得税费用 | 5,122,798 | 3,175,566.67 | 95,645.77 | -1,858,821.77 |
| 六、净利润 | 27,114,657.29 | 29,240,519.9 | 40,067,958.01 | -373,811,354.73 |
| 持续经营净利润 | 27,114,657.29 | 29,240,519.9 | 40,067,958.01 | -373,811,354.73 |
| 归属于母公司股东的净利润 | 27,114,657.29 | 29,240,519.9 | 40,067,958.01 | -373,811,354.73 |
| (一)基本每股收益 | 0.46 | 0.5 | 0.68 | -6.38 |
| (二)稀释每股收益 | 0.46 | 0.5 | 0.68 | -6.38 |
| 九、综合收益总额 | 27,114,657.29 | 29,240,519.9 | 40,067,958.01 | -373,811,354.73 |
| 归属于母公司股东的综合收益总额 | 27,114,657.29 | 29,240,519.9 | 40,067,958.01 | -373,811,354.73 |
| 公告日期 | 2024-10-26 | 2024-08-31 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |